Randomized, Double-blind, Placebo-controlled Study of the Tolerability and Pharmacokinetics of Ascending Single and 14-day Repeated Oral Doses of ZL-2102 With a Pilot Investigation of Food Effect in Healthy Male Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 16 Jun 2017
At a glance
- Drugs ZL 2102 (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease; Idiopathic pulmonary fibrosis
- Focus Adverse reactions; First in man; Pharmacokinetics
- 13 Jun 2017 Planned End Date changed from 1 Dec 2015 to 1 Aug 2017.
- 13 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated